Iatrogenic hypoglycemia causes recurrent morbidity in most people with type 1 diabetes and
many with type 2 diabetes, and it is sometimes fatal. The barrier of hypoglycemia generally …

Hypoglycemia unawareness (HU) is defined at the onset of neuroglycopenia before the
appearance of autonomic warning symptoms. It is a major limitation to achieving tight …

People with type 2 diabetes form a heterogeneous group. Consequently, treatment
regimens and therapeutic targets should be individualized. The treatment of type 2 diabetes …

OBJECTIVE—To compare the abilities and associated hypoglycemia risks of insulin
glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7 …

Aims/hypothesis The aim of the study was to compare the efficacy and safety of liraglutide in
type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly, B31Arg, B32Arg human …

In the 1990s, the value of glycemic control in the management of diabetes became
incontrovertible. The interest in producing insulin formulations that are safer than previous …

Variability in the effect of subcutaneously administered insulin represents a major challenge
in insulin therapy where precise dosing is required in order to achieve targeted glucose …

Background The results of using status measures to identify any changes in treatment
satisfaction strongly suggest a need for specific change instruments designed to overcome …

Until recently, the majority of cases of diabetes mellitus among children and adolescents
were immune-mediated type 1a diabetes. Obesity has led to a dramatic increase in the …

The importance of strict glycemic control to limit the risk of diabetic vascular complications is
indisputable, but many barriers obstruct its attainment. Hypoglycemia is recognized to be a …